(Q36191034)

12 August 2017

1 reference

title

The safety of fondaparinux for the prevention and treatment of venous thromboembolism (English)

1 reference

12 August 2017

main subject

venous thromboembolism

1 reference

Alexander G G Turpie

1

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 July 2005

1 reference

Expert Opinion on Drug Safety

12 August 2017

published in

1 reference

12 August 2017

volume

4

1 reference

12 August 2017

issue

4

1 reference

12 August 2017

page(s)

707-721

1 reference

Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.707

A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.707

Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.707

Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.707

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.707

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.707

Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.707

Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.707

A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.707

A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.707

Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.707

Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.707

Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.707

Successful use of Arixtra in a patient with paroxysmal nocturnal hemoglobinuria, Budd-Chiari syndrome and heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.707

Ximelagatran: a new oral anticoagulant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.707

Minor transplacental passage of fondaparinux in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.4.707

21 January 2018

Identifiers

DOI

10.1517/14740338.4.4.707

1 reference

12 August 2017

1 reference